Skip to main content
OpenTrials
Completed

NCT Number: NCT04927234

Foot and Ankle Post-operative Oedema Management Using Geko™

The multicentre randomised geko™ Foot and Ankle Trial will prospectively and systematically collect clinical data on patients randomised, on a 1:1 basis, to either standard care or standard care plus geko™ therapy to assess oedema management and patient outcomes during a follow-up period of up to three months post-surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Clinic Barcelona, Barcelona, Spain

Loading trial locations.

About this study

The geko™ device has a wide range of clinical applications including the post-operative management of oedema.

Although many short-term acute studies have been completed using the device, little clinical data has been collected on the effect of geko™ use in current standard care pathways for oedema management on patient outcomes during long term follow-up after surgery.

This study is an open label, multi-centre prospective randomised study. The study patient population will be randomised on a 1:1 basis into two groups of 61 patients each. These groups are defined as Group A patients who receive geko™ therapy and SC i.e. the intervention group and Group B patients who receive Standard Care (SC) only i.e. no intervention. The participants will be assessed pre-surgery and up to 90 days post-surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥ 18 years
  • Intact healthy skin at the site of geko™ device application.
  • Patients that have been listed for forefoot and / or hindfoot surgery
  • Patient understands and is willing to participate in the study and can comply with study procedures
  • Patient is willing and able to give written informed consent

Exclusion criteria

  • Pregnant
  • Use of any other neuro-modulation device.
  • Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.
  • No response to geko™ therapy i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting
  • Participation in any other clinical study that may interfere with the outcome of either study

Treatment and study plan

geko™ therapy

Device

Neuro-muscular electrical stimulation of the peroneal nerve

Other names: geko, NMES

Primary outcomes

  1. Assessment of post-operative oedema formation using the figure-of-eight tape measurement

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method

  2. Assessment of post-operative oedema formation using the pitting oedema scale

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using the pitting oedema scale, where following a 2 second firm thumb press, 0 (min) indicates no oedema and 4 (max) is a very deep pit.

  3. Assessment of post-operative oedema formation using bioimpedance analysis (US sites only)

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using a bioimpedance device to measure resistance to electrical current in both legs and calculating the percentage difference between the operated leg and the contralateral limb.

Secondary outcomes

  1. Incidence of Adverse Events in each group

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

  2. Incidence of device deficiencies

    Time frame: from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery

    To assess the number of geko device deficiencies (if any)

  3. Change in pain level using a visual analogue scale (VAS) score

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    Assessing pain levels using a visual analogue scale (VAS) score, where 0 means no pain and 100 is the worst pain possible.

  4. Incidence of surgical wound healing

    Time frame: From surgery until up to 90 days post-surgery

    Visually assessing the surgical wound healing status as either healed/progressing/static/deteriorating/severe.

  5. Change in analgesia dosage

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    Assessing changes in dosage of recorded analgesic medication taken by the patient

  6. Change in analgesia frequency

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    Assessing changes of frequency of recorded analgesic medication taken by the patient

  7. Change in patient reported outcomes via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

    Domains that are assessed in this questionnaire include walking/standing, pain and social interaction. Scores will range from 0 to 100, where 100 is most severe.

Sponsors and collaborators

Lead sponsor

Firstkind Ltd

Industry

Registry information

Official study title

Postoperative Oedema Management of Foot and Ankle Patients With Neuromuscular Electro-stimulation of the Peroneal Nerve Using Geko™

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jun 15, 2021
Registry last updated
Feb 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.